From the helm: Amplia Therapeutics (ASX:ATX), CEO & MD, Christopher Burns & Bell Potter Analyst, Thomas Wakim.

Bell Direct
March 20, 2026

In this episode of From the Helm, Grady is joined by Amplia Therapeutics (ASX:ATX) CEO & MD Dr Christopher Burns & Bell Potter Analyst Thomas Wakim to unpack the ongoing clinical trials for their prospective treatment drug for pancreatic cancer, and its substantial market opportunities in the US.

Ads

Bell Direct | SIMPLĂ‹ AS

Bell Direct
April 27, 2020

Morning Bell 27 April

Jessica Amir
April 27, 2020

Weekly Wrap 24 April

Jessica Amir
April 24, 2020

Morning Bell 24 April

Jessica Amir
April 24, 2020

Morning Bell 23 April

Jessica Amir
April 23, 2020

Market Update 22 April

Jessica Amir
April 22, 2020

Market Update 21 April

Jessica Amir
April 21, 2020

Market Update 20 April

Jessica Amir
April 20, 2020

Weekly Wrap 17 April

Jessica Amir
April 17, 2020

Market Update 17 April

Jessica Amir
April 17, 2020